In experimental
cerebral ischemia,
melanocortin MC4 receptor agonists induce neuroprotection and neurogenesis with subsequent long-lasting functional recovery. Here we investigated the molecular mechanisms underlying
melanocortin-induced neurogenesis. Gerbils were subjected to transient global
cerebral ischemia, then they were treated every 12 h, and until sacrifice, with
5-bromo-2'-deoxyuridine (
BrdU; to label proliferating cells), and the
melanocortin analog [Nle(4),d-Phe(7)]α-
melanocyte-stimulating hormone (NDP-α-
MSH) or saline. NDP-α-
MSH increased hippocampus dentate gyrus (DG) expression of Wnt-3A, β-
catenin, Sonic hedgehog (Shh), Zif268,
interleukin-10 (IL-10) and doublecortin (DCX), as detected at days 3, 6 and 10 after the ischemic insult. Further, an elevated number of
BrdU immunoreactive cells was found at days 3 and 10, and an improved histological picture with reduced neuronal loss at day 10, associated with learning and memory recovery. Pharmacological blockade of the Wnt-3A/β-
catenin and Shh pathways, as well as of
melanocortin MC4 receptors, prevented all effects of NDP-α-
MSH. These data indicate that, in experimental
brain ischemia, treatment with
melanocortins acting at MC4 receptors induces neural stem/progenitor cell proliferation in the DG by promptly and effectively triggering the canonical Wnt-3A/β-
catenin and Shh signaling pathways. Activation of these pathways is associated with up-regulation of the repair factor Zif268 and the neurogenesis facilitating factor
IL-10, and it seems to address mainly toward a neuronal fate, as indicated by the increase in DCX positive cells.